{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:04:30Z","timestamp":1789405470847,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T00:00:00Z","timestamp":1410393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T00:00:00Z","timestamp":1410393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim Care Resp Med"],"DOI":"10.1038\/npjpcrm.2014.54","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T09:47:36Z","timestamp":1410428856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Interstitial lung disease: raising the index of suspicion in primary care"],"prefix":"10.1038","volume":"24","author":[{"given":"Joseph","family":"D Zibrak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,11]]},"reference":[{"key":"BFnpjpcrm201454_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society","year":"2002","unstructured":"American Thoracic Society. American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277\u2013304.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1164\/ajrccm.150.4.7921471","volume":"150","author":"DB Coultas","year":"1994","unstructured":"Coultas DB, Zumwalt RE, Black WC, Sobonya RE . The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967\u2013972.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.rmed.2006.10.002","volume":"101","author":"HR Collard","year":"2007","unstructured":"Collard HR, Tino G, Noble PW, Shreve MA, Michaels M, Carlson B et al. Patient experiences with pulmonary fibrosis. Respir Med 2007; 101: 1350\u20131354.","journal-title":"Respir Med"},{"key":"BFnpjpcrm201454_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733\u2013748.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T . Drug induced interstitial lung disease. Open Respir Med J 2012; 6: 63\u201374.","journal-title":"Open Respir Med J"},{"key":"BFnpjpcrm201454_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1479972310388352","volume":"7","author":"S de Boer","year":"2010","unstructured":"de Boer S, Wilsher M. Review series: aspects of interstitial lung disease. Sarcoidosis. Chron Respir Dis 2010; 7: 247\u2013258.","journal-title":"Chron Respir Dis"},{"key":"BFnpjpcrm201454_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","volume":"183","author":"AL Olson","year":"2011","unstructured":"Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183: 372\u2013378.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00131912","volume":"42","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42: 750\u2013757.","journal-title":"Eur Respir J"},{"key":"BFnpjpcrm201454_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1513\/pats.200601-005TK","volume":"3","author":"DS Kim","year":"2006","unstructured":"Kim DS, Collard HR, King TE Jr . Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285\u2013292.","journal-title":"Proc Am Thorac Soc"},{"key":"BFnpjpcrm201454_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1183\/09031936.00077309","volume":"35","author":"C Vancheri","year":"2010","unstructured":"Vancheri C, Failla M, Crimi N, Raghu G . Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496\u2013504.","journal-title":"Eur Respir J"},{"key":"BFnpjpcrm201454_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1513\/pats.200512-137TK","volume":"3","author":"WE Lawson","year":"2006","unstructured":"Lawson WE, Loyd JE . The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease? Proc Am Thorac Soc 2006; 3: 345\u2013349.","journal-title":"Proc Am Thorac Soc"},{"key":"BFnpjpcrm201454_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1183\/09059180.00002512","volume":"21","author":"L Nalysnyk","year":"2012","unstructured":"Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D . Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355\u2013361.","journal-title":"Eur Respir Rev"},{"key":"BFnpjpcrm201454_CR14","unstructured":"Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. (2014). http:\/\/www.goldcopd.org (accessed 11 May 2014)."},{"key":"BFnpjpcrm201454_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1183\/09031936.00038709","volume":"35","author":"V Cottin","year":"2010","unstructured":"Cottin V, Le PJ, Prevot G, Mal H, Humbert M, Simonneau G et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105\u2013111.","journal-title":"Eur Respir J"},{"key":"BFnpjpcrm201454_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1183\/09031936.05.00035205","volume":"26","author":"R Pellegrino","year":"2005","unstructured":"Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948\u2013968.","journal-title":"Eur Respir J"},{"key":"BFnpjpcrm201454_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr . Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431\u2013440.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR18","unstructured":"National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summary on breathlessness (2014). http:\/\/cks.nice.org.uk\/breathlessness#!scenariorecommendation:7 (accessed 11 May 2014)."},{"key":"BFnpjpcrm201454_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1148\/radiol.2361031674","volume":"236","author":"DA Lynch","year":"2005","unstructured":"Lynch DA, Travis WD, Muller NL, Galvin JR, Hansell DM, Grenier PA et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005; 236: 10\u201321.","journal-title":"Radiology"},{"key":"BFnpjpcrm201454_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/aje\/152.4.307","volume":"152","author":"KB Baumgartner","year":"2000","unstructured":"Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000; 152: 307\u2013315.","journal-title":"Am J Epidemiol"},{"key":"BFnpjpcrm201454_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1183\/09031936.00001612","volume":"40","author":"V Cottin","year":"2012","unstructured":"Cottin V, Cordier JF . Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012; 40: 519\u2013521.","journal-title":"Eur Respir J"},{"key":"BFnpjpcrm201454_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12016-010-8211-5","volume":"40","author":"AT Borchers","year":"2011","unstructured":"Borchers AT, Chang C, Keen CL, Gershwin ME . Idiopathic pulmonary fibrosis-an epidemiological and pathological review. Clin Rev Allergy Immunol 2011; 40: 117\u2013134.","journal-title":"Clin Rev Allergy Immunol"},{"key":"BFnpjpcrm201454_CR23","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1136\/thx.2008.101691","volume":"63","author":"B Bradley","year":"2008","unstructured":"Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: v1\u201358.","journal-title":"Thorax"},{"key":"BFnpjpcrm201454_CR24","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083\u20132092.","journal-title":"N Engl J Med"},{"key":"BFnpjpcrm201454_CR25","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071\u20132082.","journal-title":"N Engl J Med"},{"key":"BFnpjpcrm201454_CR26","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ . Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968\u20131977.","journal-title":"N Engl J Med"},{"key":"BFnpjpcrm201454_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","volume":"186","author":"I Noth","year":"2012","unstructured":"Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88\u201395.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR28","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","volume":"370","author":"FJ Martinez","year":"2014","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093\u20132101.","journal-title":"N Engl J Med"},{"key":"BFnpjpcrm201454_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1590\/S0004-28032011000200002","volume":"48","author":"RV Soares","year":"2011","unstructured":"Soares RV, Forsythe A, Hogarth K, Sweiss NJ, Noth I, Patti MG . Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol 2011; 48: 91\u201397.","journal-title":"Arq Gastroenterol"},{"key":"BFnpjpcrm201454_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1183\/09031936.06.00037005","volume":"27","author":"G Raghu","year":"2006","unstructured":"Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136\u2013142.","journal-title":"Eur Respir J"},{"key":"BFnpjpcrm201454_CR31","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","volume":"184","author":"JS Lee","year":"2011","unstructured":"Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390\u20131394.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/2045-8932.94842","volume":"2","author":"RW Hallowell","year":"2012","unstructured":"Hallowell RW, Reed RM, Fraig M, Horton MR, Girgis RE . Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Pulm Circ 2012; 2: 101\u2013106.","journal-title":"Pulm Circ"},{"key":"BFnpjpcrm201454_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000327918","volume":"82","author":"G Pitsiou","year":"2011","unstructured":"Pitsiou G, Papakosta D, Bouros D . Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration 2011; 82: 294\u2013304.","journal-title":"Respiration"},{"key":"BFnpjpcrm201454_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1164\/rccm.200805-725OC","volume":"178","author":"RB Hubbard","year":"2008","unstructured":"Hubbard RB, Smith C, Le JI, Gribbin J, Fogarty AW . The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178: 1257\u20131261.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFnpjpcrm201454_CR35","doi-asserted-by":"crossref","unstructured":"Holland A, Hill C . Physical training for interstitial lung disease. Cochrane Database Syst Rev 2008; (4): CD006322.","DOI":"10.1002\/14651858.CD006322.pub2"},{"key":"BFnpjpcrm201454_CR36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1183\/09031936.00081512","volume":"42","author":"P Huppmann","year":"2013","unstructured":"Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Sch\u00f6nheit-Kenn U, Neurohr C et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2013; 42: 444\u2013453.","journal-title":"Eur Respir J"},{"key":"BFnpjpcrm201454_CR37","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.healun.2006.03.011","volume":"25","author":"JB Orens","year":"2006","unstructured":"Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745\u2013755.","journal-title":"J Heart Lung Transplant"}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201454","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T04:03:25Z","timestamp":1672977805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npjpcrm201454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,11,27]]}},"alternative-id":["BFnpjpcrm201454"],"URL":"https:\/\/doi.org\/10.1038\/npjpcrm.2014.54","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,11]]},"assertion":[{"value":"1 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JDZ is a member of the InterMune Pharmaceuticals Clinical Advisory Board. DP has been a consultant to and\/or member of the advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Medapharma, Merck, Mundipharma, Napp, Novartis, Nycomed, Pfizer, Sandoz and Teva. He or his research team have received grants and support for research in respiratory disease from the following organisations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Orion, Pfizer, Takeda and Teva. He has received payment for lectures from Activaero, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Napp, Novartis, Pfizer and Teva, and has been paid for development of educational materials by Boehringer Ingelheim and GlaxoSmithKline. He has been reimbursed for travel expenses by Boehringer Ingelheim, Merck, Mundipharma Napp, Novartis and Teva. He holds shares in AKL, which produces phytopharmaceuticals and owns 80% of Research in Real Life and its subsidiary social enterprise Optimum Patient Care.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14054"}}